ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma
- 27 June 1998
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 351 (9120), 1911-1913
- https://doi.org/10.1016/s0140-6736(97)11419-2
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A common mutation (G-455--> A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on the Copenhagen City Heart Study.JCI Insight, 1997
- Genetic risk factors for chronic obstructive pulmonary diseaseEuropean Respiratory Journal, 1997
- A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease.JCI Insight, 1997
- Protection against bronchial asthma by CFTR ΔF508 mutation: A heterozygote advantage in cystic fibrosisNature Medicine, 1995
- Genetic analysis of cystic fibrosis in Denmark. Implications for genetic counselling, carrier diagnosis and prenatal diagnosisActa Paediatrica, 1992
- Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis.Thorax, 1987
- Bronchial hyperreactivity in cystic fibrosis and asthmaThe Journal of Pediatrics, 1978
- Prevalence of atopy and exercise-induced bronchial lability in relatives of patients with cystic fibrosis.Archives of Disease in Childhood, 1975
- THE PREVALENCE OF RESPIRATORY DISEASE IN HETEROZYGOTES FOR THE GENE FOR FIBROCYSTIC DISEASE OF THE PANCREASThe Lancet, 1963
- Anamnesis, Sweat Electrolyte and Pulmonary Function Studies in Parents of Patients with Cystic Fibrosis of the PancreasActa Paediatrica, 1963